by Summary:
“The Oxford vaccine is… striking, since the point was to pay researchers, but not to rely on patent monopolies to generate large profits.” – Economist Dean BakerThe world is abuzz today after a team of medical researchers from Oxford University in the United Kingdom announced that advanced trials of their experimental coronavirus vaccine were a roaring success, with the vaccine possibly being rolled out before Christmas. Testing was done on 24,000 volunteers in the U.K, Brazil, and South Africa, with an average effectiveness of over 70%. However, when the vaccine was administered as a half dose, then patients were later given a full one, effectiveness increased to 90%. Encouragingly, there were no serious side effects registered among any of the volunteers, none of whom had to go to the
Topics:
Mike Norman considers the following as important:
This could be interesting, too:
“The Oxford vaccine is… striking, since the point was to pay researchers, but not to rely on patent monopolies to generate large profits.” – Economist Dean BakerThe world is abuzz today after a team of medical researchers from Oxford University in the United Kingdom announced that advanced trials of their experimental coronavirus vaccine were a roaring success, with the vaccine possibly being rolled out before Christmas. Testing was done on 24,000 volunteers in the U.K, Brazil, and South Africa, with an average effectiveness of over 70%. However, when the vaccine was administered as a half dose, then patients were later given a full one, effectiveness increased to 90%. Encouragingly, there were no serious side effects registered among any of the volunteers, none of whom had to go to the
Topics:
Mike Norman considers the following as important:
This could be interesting, too:
Lars Pålsson Syll writes Klas Eklunds ‘Vår ekonomi’ — lärobok med stora brister
New Economics Foundation writes We need more than a tax on the super rich to deliver climate and economic justice
Robert Vienneau writes Profits Not Explained By Merit, Increased Risk, Increased Ability To Compete, Etc.
Lars Pålsson Syll writes Ekonomisk politik och finanspolitiska ramverk
“The Oxford vaccine is… striking, since the point was to pay researchers, but not to rely on patent monopolies to generate large profits.” – Economist Dean Baker
The world is abuzz today after a team of medical researchers from Oxford University in the United Kingdom announced that advanced trials of their experimental coronavirus vaccine were a roaring success, with the vaccine possibly being rolled out before Christmas. Testing was done on 24,000 volunteers in the U.K, Brazil, and South Africa, with an average effectiveness of over 70%. However, when the vaccine was administered as a half dose, then patients were later given a full one, effectiveness increased to 90%. Encouragingly, there were no serious side effects registered among any of the volunteers, none of whom had to go to the hospital as a result of being immunized. The U.K. government has already ordered 100 million doses.